Least burdensome
This article was originally published in The Gray Sheet
Executive Summary
Appeals of decisions by FDA's Office of Device Evaluation are best addressed to the branch chief, deputy director, or director of the appropriate review division, FDA and the Least Burdensome Industry Task Force recommend in a July 31 document. If "least burdensome" disputes are still unresolved, a firm may contact the ODE program operations staff, and if necessary, file an appeal under 21 CFR 10.75 with the ODE director. While the document suggests that the Center for Devices and Radiological Health ombudsman be contacted after a formal appeal fails, it notes that the ombudsman may be contacted at any point in the process. In addition to deficiency letters, the appeals mechanism may be used if any "aspect of a guidance document poses an inappropriate burden"
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.